Geoffrey S Johnson (Geoffrey Johnson)

Publication Activity (10 Years)

Years Active: 2019-2022
Publications (10 Years): 3

Top Topics

Signaling Pathway

Top Venues

Pharmaceutical research

This page only lists publications with an associated author ORCID identifier.

Publications

Debra J Tompson, Mark Whitaker, Rennan Pan, Geoffrey S Johnson, Teresa Fuller, Vanessa Zann, Litza McKenzie, Kathy Abbott Banner, Simon J Hawkins, Marcy Powell
Development of a Once-Daily Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772 using DiffCORE Technology. Pharmaceutical research 39 (1) (2022)
Debra J Tompson, Mark Whitaker, Rennan Pan, Geoffrey S Johnson, Teresa Fuller, Litza McKenzie, Vanessa Zann, Marcy Powell, Kathy Abbott Banner, Simon J Hawkins
Development of a Prototype, Once-Daily, Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772. Pharmaceutical research 38 (7) (2021)
Kyong-Mi Chang, Daniel Traum, Jang-June Park, Suzanne Ho, Keisuke Ojiro, David K Wong, Abdus S Wahed, Norah A Terrault, Mandana Khalili, Richard K Sterling, Harry L A Janssen, Margaret C Shuhart, Daryl T Lau, Lewis Rowland Roberts, Geoffrey S Johnson, David E Kaplan, Michael R Betts, William M Lee, Anna S F Lok, null null
Distinct phenotype and function of circulating Vδ1+ and Vδ2+ γδT-cells in acute and chronic hepatitis B. PLoS pathogens 15 (4) (2019)